These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 30352802)

  • 1. Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties.
    Cao L; Weetall M; Trotta C; Cintron K; Ma J; Kim MJ; Furia B; Romfo C; Graci JD; Li W; Du J; Sheedy J; Hedrick J; Risher N; Yeh S; Qi H; Arasu T; Hwang S; Lennox W; Kong R; Petruska J; Moon YC; Babiak J; Davis TW; Jacobson A; Almstead NG; Branstrom A; Colacino JM; Peltz SW
    Mol Cancer Ther; 2019 Jan; 18(1):3-16. PubMed ID: 30352802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes.
    Kayamori K; Nagai Y; Zhong C; Kaito S; Shinoda D; Koide S; Kuribayashi W; Oshima M; Nakajima-Takagi Y; Yamashita M; Mimura N; Becker HJ; Izawa K; Yamazaki S; Iwano S; Miyawaki A; Ito R; Tohyama K; Lennox W; Sheedy J; Weetall M; Sakaida E; Yokote K; Iwama A
    Blood Adv; 2021 Jan; 5(2):438-450. PubMed ID: 33496740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines.
    Luban J; Sattler RA; Mühlberger E; Graci JD; Cao L; Weetall M; Trotta C; Colacino JM; Bavari S; Strambio-De-Castillia C; Suder EL; Wang Y; Soloveva V; Cintron-Lue K; Naryshkin NA; Pykett M; Welch EM; O'Keefe K; Kong R; Goodwin E; Jacobson A; Paessler S; Peltz SW
    Virus Res; 2021 Jan; 292():198246. PubMed ID: 33249060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SAR studies toward discovery of emvododstat (PTC299), a potent dihydroorotate dehydrogenase (DHODH) inhibitor.
    Baiazitov RY; Qi H; Arasu T; Lennox W; Cao L; Weetall M; Furia B; Zhuo J; Choi S; Kim MJ; Sheedy J; Davis T; Moon YC
    Eur J Med Chem; 2022 Dec; 244():114826. PubMed ID: 36242990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines.
    Luban J; Sattler R; Mühlberger E; Graci JD; Cao L; Weetall M; Trotta C; Colacino JM; Bavari S; Strambio-De-Castillia C; Suder EL; Wang Y; Soloveva V; Cintron-Lue K; Naryshkin NA; Pykett M; Welch EM; O'Keefe K; Kong R; Goodwin E; Jacobson A; Paessler S; Peltz S
    bioRxiv; 2020 Aug; ():. PubMed ID: 32793904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emvododstat, a Potent Dihydroorotate Dehydrogenase Inhibitor, Is Effective in Preclinical Models of Acute Myeloid Leukemia.
    Branstrom A; Cao L; Furia B; Trotta C; Santaguida M; Graci JD; Colacino JM; Ray B; Li W; Sheedy J; Mollin A; Yeh S; Kong R; Sheridan R; Baird JD; O'Keefe K; Spiegel R; Goodwin E; Keating S; Weetall M
    Front Oncol; 2022; 12():832816. PubMed ID: 35223511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase.
    McDonald G; Chubukov V; Coco J; Truskowski K; Narayanaswamy R; Choe S; Steadman M; Artin E; Padyana AK; Jin L; Ronseaux S; Locuson C; Fan ZP; Erdmann T; Mann A; Hayes S; Fletcher M; Nellore K; Rao SS; Subramanya H; Reddy KS; Panigrahi SK; Antony T; Gopinath S; Sui Z; Nagaraja N; Dang L; Lenz G; Hurov J; Biller SA; Murtie J; Marks KM; Ulanet DB
    Mol Cancer Ther; 2020 Dec; 19(12):2502-2515. PubMed ID: 33082276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer.
    Madak JT; Bankhead A; Cuthbertson CR; Showalter HD; Neamati N
    Pharmacol Ther; 2019 Mar; 195():111-131. PubMed ID: 30347213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydroorotate dehydrogenase in oxidative phosphorylation and cancer.
    Boukalova S; Hubackova S; Milosevic M; Ezrova Z; Neuzil J; Rohlena J
    Biochim Biophys Acta Mol Basis Dis; 2020 Jun; 1866(6):165759. PubMed ID: 32151633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dihydroorotate Dehydrogenase Inhibitors Promote Cell Cycle Arrest and Disrupt Mitochondria Bioenergetics in Ramos Cells.
    Kadir MFA; Othman S; Nellore K
    Curr Pharm Biotechnol; 2020; 21(15):1654-1665. PubMed ID: 32525770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the de novo pyrimidine biosynthesis pathway limits ribosomal RNA transcription causing nucleolar stress in glioblastoma cells.
    Lafita-Navarro MC; Venkateswaran N; Kilgore JA; Kanji S; Han J; Barnes S; Williams NS; Buszczak M; Burma S; Conacci-Sorrell M
    PLoS Genet; 2020 Nov; 16(11):e1009117. PubMed ID: 33201894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A carboxylic acid isostere screen of the DHODH inhibitor Brequinar.
    DeRatt LG; Christine Pietsch E; Tanner A; Shaffer P; Jacoby E; Wang W; Kazmi F; Zhang X; Attar RM; Edwards JP; Kuduk SD
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127589. PubMed ID: 33007394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells.
    Mohamad Fairus AK; Choudhary B; Hosahalli S; Kavitha N; Shatrah O
    Biochimie; 2017 Apr; 135():154-163. PubMed ID: 28196676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pivotal role of dihydroorotate dehydrogenase as a therapeutic target in adult T-cell leukemia.
    Ishikawa C; Mori N
    Eur J Haematol; 2024 Jul; 113(1):99-109. PubMed ID: 38558052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional expression of human dihydroorotate dehydrogenase (DHODH) in pyr4 mutants of ustilago maydis allows target validation of DHODH inhibitors in vivo.
    Zameitat E; Freymark G; Dietz CD; Löffler M; Bölker M
    Appl Environ Microbiol; 2007 May; 73(10):3371-9. PubMed ID: 17369345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel series of human dihydroorotate dehydrogenase inhibitors discovered by in vitro screening: inhibition activity and crystallographic binding mode.
    Zeng T; Zuo Z; Luo Y; Zhao Y; Yu Y; Chen Q
    FEBS Open Bio; 2019 Aug; 9(8):1348-1354. PubMed ID: 31087527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors.
    Vyas VK; Ghate M
    Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of Tetrahydroindazoles as Inhibitors of Human Dihydroorotate Dehydrogenase and Evaluation of Their Activity and In Vitro Metabolic Stability.
    Popova G; Ladds MJGW; Johansson L; Saleh A; Larsson J; Sandberg L; Sahlberg SH; Qian W; Gullberg H; Garg N; Gustavsson AL; Haraldsson M; Lane D; Yngve U; Lain S
    J Med Chem; 2020 Apr; 63(8):3915-3934. PubMed ID: 32212728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stress-Regulated Protein Translation.
    Weetall M; Davis T; Elfring G; Northcutt V; Cao L; Moon YC; Riebling P; Dali M; Hirawat S; Babiak J; Colacino J; Almstead N; Spiegel R; Peltz SW
    Clin Pharmacol Drug Dev; 2016 Jul; 5(4):296-305. PubMed ID: 27310330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a biomarker to monitor target engagement after treatment with dihydroorotate dehydrogenase inhibitors.
    Pontikos MA; Leija C; Zhao Z; Wang X; Kilgore J; Tornesi B; Adenmatten N; Phillips MA; Williams NS
    Biochem Pharmacol; 2022 Oct; 204():115237. PubMed ID: 36055381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.